Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2023 08:00 ET | Source: Pasithea

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...
February 23, 2023 08:00 ET | Source: Pasithea

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
February 16, 2023 07:30 ET | Source: Pasithea

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

PALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...
January 18, 2023 08:00 ET | Source: Pasithea

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 -- MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...
December 14, 2022 17:18 ET | Source: Pasithea

Majority of Stockholders Support Pasithea Directors at Special Meeting

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
December 12, 2022 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
December 06, 2022 08:00 ET | Source: Pasithea

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

MIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
November 28, 2022 19:05 ET | Source: Pasithea

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
October 17, 2022 08:00 ET | Source: Pasithea

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

MIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...
October 12, 2022 08:00 ET | Source: Pasithea

Pasithea Therapeutics Acquires AlloMek Therapeutics

-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right